<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417883</url>
  </required_header>
  <id_info>
    <org_study_id>PT15-920</org_study_id>
    <nct_id>NCT02417883</nct_id>
  </id_info>
  <brief_title>Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease</brief_title>
  <acronym>FST-IFTA</acronym>
  <official_title>Furosemide Stress Test as a Predictor of Tubular Atrophy and Interstitial Fibrosis in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cardiologia Ignacio Chavez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In kidney diseases, tubule-interstitium has become much more relevant, as formerly only the
      glomerulus was considered to have the main importance. Kidney's tubular atrophy and
      interstitital fibrosis is now recognized as long term prognostic value. We aim to evaluate
      the function of the kidney's tubule-interstitium through furosemide excretion after
      intravenous administration of this drug, and correlate the rate of excretion of furosemide
      with interstitial fibrosis findings in scheduled kidney biopsy for patients with chronic
      kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients scheduled for kidney biopsy will be invited to participate in a standard
      isovolemic furosemide stress test before the biopsy procedure. The latter will consist in 1.5
      miligrams per kilogram of weight of intravenous furosemide administration, with urinary
      output follow up and measurement. The urinary output will be replaced intravenously with
      normal saline to avoid dehydration and/or hypotension. A standard 5ml sample of blood will be
      taken before the test and aliquots of urine before and after furosemide administration will
      be frozen.

      After completion of the formely mentioned test, patients will proceed to their scheduled
      kidney biopsy along with interventions considered appropiate by their attending physician.

      Kidney biopsy sample will be examined by histopathology service and the degree of
      interstitial fibrosis will be described. The degree of fibrosis will be correlated with the
      degree furosemide excretion and urinary output.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Output</measure>
    <time_frame>6 hours</time_frame>
    <description>Cuantify urinary output after furosemide administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Furosemide excretion rate</measure>
    <time_frame>6hrs</time_frame>
    <description>Cuantify furosemide excretion in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Fibrosis</measure>
    <time_frame>3 days</time_frame>
    <description>Measure interstitial fibrosis in kidney biopsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Furosemide Stress Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Evaluate urinary excretion rate fo furosemide</description>
    <arm_group_label>Furosemide Stress Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Accept to participate (informed consent)

          -  Legal age or older

          -  An estimated glomerular filtration rate greater than 15ml/min/1.73m2, calculated by
             CKD-EPI.

        Exclusion Criteria:

          -  Known Alergic reaction to furosemide

          -  Contraindication to kidney biopsy

          -  Patient already in renal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Madero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief of the Nephrology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magdalena Madero, MD</last_name>
    <phone>+55-5573-2911</phone>
    <phone_ext>1262</phone_ext>
    <email>madero.magdalena@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos A Garza, MD</last_name>
    <phone>+55-5573-2911</phone>
    <phone_ext>1262</phone_ext>
    <email>gza.carlos@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Ignacio Chavez</name>
      <address>
        <city>Mexico city</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Madero, MD</last_name>
      <email>madero.magdalena@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010 Nov;6(11):643-56. doi: 10.1038/nrneph.2010.120. Epub 2010 Sep 14. Review.</citation>
    <PMID>20838416</PMID>
  </reference>
  <reference>
    <citation>Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs. 2007;185(1-3):222-31. Review.</citation>
    <PMID>17587828</PMID>
  </reference>
  <reference>
    <citation>Farris AB, Chan S, Climenhaga J, Adam B, Bellamy CO, Ser√≥n D, Colvin RB, Reeve J, Mengel M. Banff fibrosis study: multicenter visual assessment and computerized analysis of interstitial fibrosis in kidney biopsies. Am J Transplant. 2014 Apr;14(4):897-907. doi: 10.1111/ajt.12641. Epub 2014 Feb 20.</citation>
    <PMID>24712330</PMID>
  </reference>
  <reference>
    <citation>Farris AB, Colvin RB. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens. 2012 May;21(3):289-300. doi: 10.1097/MNH.0b013e3283521cfa. Review.</citation>
    <PMID>22449945</PMID>
  </reference>
  <reference>
    <citation>van der Voort PH, Boerma EC, Pickkers P. The furosemide stress test to predict renal function after continuous renal replacement therapy. Crit Care. 2014 May 14;18(3):429. doi: 10.1186/cc13871.</citation>
    <PMID>25033085</PMID>
  </reference>
  <results_reference>
    <citation>Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Kimmel PL, Seneff MG. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care. 2013 Sep 20;17(5):R207. doi: 10.1186/cc13015.</citation>
    <PMID>24053972</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cardiologia Ignacio Chavez</investigator_affiliation>
    <investigator_full_name>Magdalena Madero</investigator_full_name>
    <investigator_title>Chief of Nephrology Department, MD</investigator_title>
  </responsible_party>
  <keyword>Furosemide</keyword>
  <keyword>Interstitial Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

